Literature DB >> 33257451

A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae in Japan.

Sho Saito1,2,3, Kayoko Hayakawa4,2, Shinya Tsuzuki2,5, Masahiro Ishikane4,2, Maki Nagashima4, Kazuhisa Mezaki6, Yuko Sugiki7, Taichi Tajima2, Nobuaki Matsunaga2, Satoshi Ide4,3, Noriko Kinoshita4,2,3, Yoshiki Kusama2,3, Yumiko Fujitomo2, Takato Nakamoto4, Yuta Toda4, Mitsuo Kaku8, Eiichi N Kodama9, Norio Ohmagari4,2,3.   

Abstract

IMP-type carbapenemase, found in various Gram-negative bacteria, has been increasingly detected worldwide. We aimed to study the outcomes and risk factors for acquisition of IMP-type carbapenemase-producing carbapenem-resistant Enterobacteriaceae (IMP-CRE), as this has not been evaluated in detail. We conducted a matched case-case-control study of patients from whom IMP-CRE isolates were obtained. All patients who tested positive for IMP-CRE were included; they were matched with patients with carbapenem-susceptible Enterobacteriaceae (CSE) and with controls at a ratio of 1:1:2. The risk factors for acquisition for the CRE and CSE groups and mortality rates, which were calculated using multivariate logistic regression models with weighting according to the inverse probability of propensity scores, were compared. In total, 192 patients (96 patients each in the CRE and CSE groups, with 130 Enterobacter cloacae isolates and 62 Klebsiella sp. isolates) were included. The IMP-11 type was present in 43 patients, IMP-1 in 33, and IMP-60 and IMP-66 in 1 each; 31 patients with CRE (32.3%) and 34 with CSE (35.4%) developed infections. Multivariate analysis identified the following independent risk factors: gastrostomy, history of intravenous therapy or hemodialysis, and previous exposure to broad-spectrum β-lactam antibiotics, including penicillin with β-lactamase inhibitors, cephalosporins, and carbapenems. In propensity score-adjusted analysis, mortality rates for the CRE and CSE groups were similar (15.0% and 19.5%, respectively). We found that IMP-CRE may not contribute to worsened clinical outcomes, compared to CSE, and gastrostomy, previous intravenous therapy, hemodialysis, and broad-spectrum antimicrobial exposure were identified as risk factors for CRE isolation. Fluoroquinolone and aminoglycosides are potentially useful antibiotics for IMP-CRE infections.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  Enterobacteriaceae; IMP; carbapenem resistance; clinical outcomes; propensity score

Mesh:

Substances:

Year:  2021        PMID: 33257451      PMCID: PMC8092526          DOI: 10.1128/AAC.01483-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species.

Authors:  S M Diene; J-M Rolain
Journal:  Clin Microbiol Infect       Date:  2014-06-14       Impact factor: 8.067

2.  Risk factors for fecal carriage of IMP-6-producing Enterobacteriaceae at a long-term care hospital in Japan: A follow-up report from the northern Osaka multicentre study group.

Authors:  Hideharu Hagiya; Norihisa Yamamoto; Ryuji Kawahara; Yukihiro Akeda; Rathina Kumar Shanmugakani; Akiko Ueda; Isao Nishi; Rumiko Asada; Hisao Yoshida; Kazunori Tomono
Journal:  J Infect Chemother       Date:  2018-04-12       Impact factor: 2.211

Review 3.  The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace.

Authors:  Latania K Logan; Robert A Weinstein
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

4.  Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae at a Turkish centre: Is the increase of resistance a threat for Europe?

Authors:  Aslıhan Candevir Ulu; Tülin Güven Gökmen; Filiz Kibar; Behice Kurtaran; Cansu Önlen; Ferit Kuşçu; Ayşe Seza İnal; Süheyla Kömür; Akgün Yaman; Hasan Salih Zeki Aksu; Yeşim Taşova
Journal:  J Glob Antimicrob Resist       Date:  2017-07-22       Impact factor: 4.035

Review 5.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

6.  Bloodstream infections caused by IMP-8-producing Enterobacteriaceae isolates: the need for clinical laboratory detection of metallo-β-lactamases?

Authors:  J J Yan; N Y Lee; H M Chen; M C Wang; W C Ko; L H Tsai; J J Wu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09-23       Impact factor: 3.267

7.  Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.

Authors:  Leanne B Gasink; Paul H Edelstein; Ebbing Lautenbach; Marie Synnestvedt; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2009-12       Impact factor: 3.254

8.  Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: Systematic review and meta-analysis: Mortality due to KPC Klebsiella pneumoniae infections.

Authors:  Jorge A Ramos-Castañeda; Alberto Ruano-Ravina; Raquel Barbosa-Lorenzo; Jaime E Paillier-Gonzalez; Javier C Saldaña-Campos; Diego F Salinas; Elkin V Lemos-Luengas
Journal:  J Infect       Date:  2018-03-01       Impact factor: 6.072

9.  In-vivo loss of carbapenem resistance by extensively drug-resistant Klebsiella pneumoniae during treatment via porin expression modification.

Authors:  Suzanne Bialek-Davenet; Noémie Mayer; Julia Vergalli; Marion Duprilot; Sylvain Brisse; Jean-Marie Pagès; Marie-Hélène Nicolas-Chanoine
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379

10.  Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.

Authors:  Feng Pang; Xiu-Qin Jia; Qi-Gang Zhao; Yi Zhang
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-03-23       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.